Sanket S. Dhruva

Sanket S. Dhruva

Auto-generated profile, based on publicly available information

Sanket S. Dhruva

University of California, San Francisco School of Medicine, San Francisco, CA, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2020 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
SDSanket S. Dhruva
Sanket S. Dhruva
JRJoseph S. Ross
Joseph S. Ross
JAJoseph G. Akar
Joseph G. Akar
BCBrittany Caldwell
Brittany Caldwell
KCKarla Childers
Karla Childers
NSNilay D. Shah
Nilay D. Shah
Real-world data sources, including electronic health records (EHRs) and personal digital device data, are increasingly available, but are often siloed and cannot be easily integrated for clinical, research, or regulatory purposes. We conducted a prospective cohort study of 60 patients undergoing bariatric surgery or catheter-based atrial fibrillation ablation at two U.S. tertiary care hospitals, testing the feasibility of using a patient-centered health-data-sharing platform to obtain and aggregate health data from multiple sources. We successfully obtained EHR data for all patients at both hospitals, as well as from ten additional health systems, which were successfully aggregated with pharmacy data obtained for patients using CVS or Walgreens pharmacies; personal digital device data from activity monitors, digital weight scales, and single-lead ECGs, and patient-reported outcome measure data obtained through surveys to assess post-procedure recovery and disease-specific symptoms. A patient-centered health-data-sharing platform successfully aggregated data from multiple sources.

12 January 2026 in JACC
Verified
Journal Article
Open access
RWRishi K. Wadhera
Rishi K. Wadhera
SDSanket S. Dhruva
Sanket S. Dhruva
BBBehnood Bikdeli
Behnood Bikdeli
MBMarc P. Bonaca
Marc P. Bonaca
MKMichelle M. Kittleson
Michelle M. Kittleson
LCLesley H. Curtis
Lesley H. Curtis

20 June 2022 in JACC
Verified
Journal Article
Closed access
KFKamil F. Faridi
Kamil F. Faridi
EDElias J. Dayoub
Elias J. Dayoub
JRJoseph S. Ross
Joseph S. Ross
SDSanket S. Dhruva
Sanket S. Dhruva
TATariq Ahmad
Tariq Ahmad
NDNihar R. Desai
Nihar R. Desai

1 January 2023 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
SDSanket S. Dhruva
Sanket S. Dhruva
JMJaime Murillo
Jaime Murillo
OAOmid Ameli
Omid Ameli
PMPamela E. Morin
Pamela E. Morin
DSDonna L. Spencer
Donna L. Spencer
KCKen Cohen
Ken Cohen
Spinal cord stimulators (SCSs) are neuromodulation devices implanted in the epidural space with the goal of treating chronic pain that fails to respond to conventional treatment. SCSs have been increasingly used in recent years1,2; approximately 50 000 are implanted annually in the US3 at a cost of approximately $3.5 billion.4 Some have advocated for greater use of SCSs to reduce risks of medications, including opioids and gabapentinoids.5

30 August 2022 in Journal of General Internal Medicine
Verified
Journal Article
Open access
PDF file
SDSanket S. Dhruva
Sanket S. Dhruva
JDJames Dziura
James Dziura
HBHarini Bathulapalli
Harini Bathulapalli
LRLindsey Rosman
Lindsey Rosman
AGAllison E. Gaffey
Allison E. Gaffey
SHSally G. Haskell
Sally G. Haskell
Background: There is an increasing burden of cardiovascular disease, including coronary artery disease (CAD) and heart failure (HF), among women Veterans. Clinical practice guidelines recommend multiple pharmacotherapies that can reduce risk of mortality and adverse cardiovascular outcomes. Objective: To determine if there are disparities in the use of guideline-directed medical therapy by gender among Veterans with incident CAD and HF. Design: Retrospective. Participants: Veterans (934,504; 87.8% men and 129,469; 12.2% women) returning from Operations Enduring Freedom, Iraqi Freedom, and New Dawn. Main Measures: Differences by gender in the prescription of Class 1, Level of Evidence A guideline-directed medical therapy among patients who developed incident CAD and HF at 30 days, 90 days, and 12 months after diagnosis. For CAD, medications included statins and antiplatelet therapy. For HF, medications included beta-blockers and renin-angiotensin-aldosterone system inhibitors. Key Results: Overall, women developed CAD and HF at a younger average age than men (mean 45.8 vs. 47.7 years, p<0.001; and 43.7 vs. 45.4 years, p<0.02, respectively). In the 12 months following a diagnosis of incident CAD, the odds of a woman receiving a prescription for at least one CAD drug was 0.85 (95% confidence interval [CI], 0.68–1.08) compared to men. In the 12 months following a diagnosis of incident HF, the odds of a woman receiving at least one HF medication was 0.54 (95% CI, 0.37–0.79) compared to men. Conclusions: Despite guideline recommendations, young women Veterans have approximately half the odds of being prescribed guideline-directed medical therapy within 1-year after a diagnosis of HF. These results highlight the need to develop targeted strategies to minimize gender disparities in CVD care to prevent adverse outcomes in this young and growing population.

25 January 2024 in New England Journal of Medicine
Verified
Journal Article
Closed access
JRJames C. Robinson
James C. Robinson
CWChristopher Whaley
Christopher Whaley
SDSanket S. Dhruva
Sanket S. Dhruva
Hospitals can leverage their position between the ultimate buyers and sellers of drugs to retain a substantial share of insurer pharmaceutical expenditures. In this study, we used 2020-2021 national Blue Cross Blue Shield claims data regarding patients in the United States who had drug-infusion visits for oncologic conditions, inflammatory conditions, or blood-cell deficiency disorders. Markups of the reimbursement prices were measured in terms of amounts paid by Blue Cross Blue Shield plans to hospitals and physician practices relative to the amounts paid by these providers to drug manufacturers. Acquisition-price reductions in hospital payments to drug manufacturers were measured in terms of discounts under the federal 340B Drug Pricing Program. We estimated the percentage of Blue Cross Blue Shield drug spending that was received by drug manufacturers and the percentage retained by provider organizations. The study included 404,443 patients in the United States who had 4,727,189 drug-infusion visits. The median price markup (defined as the ratio of the reimbursement price to the acquisition price) for hospitals eligible for 340B discounts was 3.08 (interquartile range, 1.87 to 6.38). After adjustment for drug, patient, and geographic factors, price markups at hospitals eligible for 340B discounts were 6.59 times (95% confidence interval [CI], 6.02 to 7.16) as high as those in independent physician practices, and price markups at noneligible hospitals were 4.34 times (95% CI, 3.77 to 4.90) as high as those in physician practices. Hospitals eligible for 340B discounts retained 64.3% of insurer drug expenditures, whereas hospitals not eligible for 340B discounts retained 44.8% and independent physician practices retained 19.1%. This study showed that hospitals imposed large price markups and retained a substantial share of total insurer spending on physician-administered drugs for patients with private insurance. The effects were especially large for hospitals eligible for discounts under the federal 340B Drug Pricing Program on acquisition costs paid to manufacturers. (Funded by Arnold Ventures and the National Institute for Health Care Management.).